Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sativex add-on therapy versus further optimized first-line antispastic therapy in multiple sclerosis spasticity
2015-004451-40Phase 4Completed
- Sponsor
- Almirall
- Start
- Dec 2015
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of cannabidiol, baclofen, tizanidine and dantrolene in multiple sclerosis (MS) and Muscle spasm (2 arms), sponsored by Almirall. Primary endpoint: 30% NRS spasticity responder rate. Started Dec 2015; status: completed.
02
Drugs
cannabidiolbaclofentizanidinedantrolene
03
Conditions
multiple sclerosis (MS)Muscle spasm
Beyond the preview
Go deeper on 2015-004451-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004451-40.